Mark Ragosa's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 39,363 Share Option done . Disclosure was reported to the exchange on Sept. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 39,363 | 39,363 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 12,275 | 12,275 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.49 per share. | 01 Sep 2025 | 2,920 | 30,125 (0%) | 0% | 33.5 | 97,791 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 2,694 | 33,045 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 2,694 | 2,694 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,861 | 31,986 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,861 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,750 | 30,351 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,750 | 3,500 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,592 | 28,601 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 1,592 | 4,773 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.28 per share. | 01 Sep 2025 | 900 | 31,086 (0%) | 0% | 34.3 | 30,852 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2025 | 18,889 | 2,036 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.89 per share. | 04 Aug 2025 | 18,889 | 27,009 (0%) | 0% | 32.9 | 621,259 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.89 per share. | 04 Aug 2025 | 18,889 | 45,898 (0%) | 0% | 22.9 | 432,369 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 18,299 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.80 per share. | 03 Jun 2025 | 18,299 | 27,009 (0%) | 0% | 28.8 | 527,011 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 03 Jun 2025 | 18,299 | 45,308 (0%) | 0% | 18 | 329,382 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 7,606 | 7,606 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 7,368 | 7,368 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,786 | 4,876 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,558 | 4,558 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.61 per share. | 29 Apr 2025 | 42,000 | 27,009 (0%) | 0% | 25.6 | 1,075,620 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.80 per share. | 29 Apr 2025 | 25,141 | 27,009 (0%) | 0% | 27.8 | 698,920 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 29 Apr 2025 | 22,000 | 69,009 (0%) | 0% | 15.5 | 341,000 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 22,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.90 per share. | 29 Apr 2025 | 21,254 | 48,263 (0%) | 0% | 16.9 | 359,193 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 21,254 | 2,471 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.95 per share. | 29 Apr 2025 | 21,254 | 27,009 (0%) | 0% | 26.9 | 572,795 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 29 Apr 2025 | 20,000 | 47,009 (0%) | 0% | 15.5 | 310,400 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 20,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 13,141 | 28,909 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 29 Apr 2025 | 13,141 | 52,150 (0%) | 0% | 17.8 | 233,384 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 12,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.92 per share. | 29 Apr 2025 | 12,000 | 39,009 (0%) | 0% | 17.9 | 215,040 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2025 | 990 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2025 | 990 | 27,488 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.37 per share. | 26 Apr 2025 | 479 | 27,009 (0%) | 0% | 21.4 | 10,234 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,694 | 2,694 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 2,694 | 27,801 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 1,303 | 26,498 (0%) | 0% | 20.3 | 26,425 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 29,480 | 29,480 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 14,765 | 14,765 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 7,382 | 7,382 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,750 | 25,132 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,750 | 3,500 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,592 | 4,773 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,592 | 26,724 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 847 | 25,877 (0%) | 0% | 21.8 | 18,439 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 770 | 25,107 (0%) | 0% | 21.8 | 16,763 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.97 per share. | 20 Mar 2025 | 15,944 | 39,326 (0%) | 0% | 13.0 | 206,794 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 15,944 | 8,374 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.11 per share. | 20 Mar 2025 | 15,944 | 23,382 (0%) | 0% | 23.1 | 368,466 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.97 per share. | 16 Mar 2025 | 11,464 | 34,846 (0%) | 0% | 13.0 | 148,688 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.10 per share. | 16 Mar 2025 | 11,464 | 23,382 (0%) | 0% | 23.1 | 264,818 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 11,464 | 33,197 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.10 per share. | 16 Mar 2025 | 8,879 | 23,382 (0%) | 0% | 23.1 | 205,105 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.97 per share. | 16 Mar 2025 | 8,879 | 32,261 (0%) | 0% | 13.0 | 115,161 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 8,879 | 24,318 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 872 | 23,830 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 872 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 448 | 23,382 (0%) | 0% | 22.6 | 10,129 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 36,372 | 28,288 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 22.25 per share. | 12 Mar 2025 | 36,372 | 22,958 (0%) | 0% | 22.3 | 809,277 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 12 Mar 2025 | 36,372 | 59,330 (0%) | 0% | 12.0 | 435,373 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 06 Dec 2024 | 18,860 | 41,818 (0%) | 0% | 11.1 | 209,346 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.38 per share. | 06 Dec 2024 | 18,860 | 22,958 (0%) | 0% | 21.4 | 403,227 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 18,860 | 21,552 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.27 per share. | 06 Dec 2024 | 8,969 | 22,958 (0%) | 0% | 21.3 | 190,771 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.76 per share. | 06 Dec 2024 | 2,406 | 25,364 (0%) | 0% | 10.8 | 25,889 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 2,406 | 24,528 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.76 per share. | 03 Dec 2024 | 8,969 | 31,927 (0%) | 0% | 10.8 | 96,506 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.45 per share. | 03 Dec 2024 | 8,969 | 22,958 (0%) | 0% | 21.4 | 192,385 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 8,969 | 33,081 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.25 per share. | 03 Dec 2024 | 5,024 | 22,958 (0%) | 0% | 21.3 | 106,760 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.76 per share. | 03 Dec 2024 | 5,024 | 27,982 (0%) | 0% | 10.8 | 54,058 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 5,024 | 28,057 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 1,123 | 26,934 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.25 per share. | 03 Dec 2024 | 1,123 | 22,958 (0%) | 0% | 21.3 | 23,864 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.76 per share. | 03 Dec 2024 | 1,123 | 24,081 (0%) | 0% | 10.8 | 12,083 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 33,150 | 33,150 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 6,365 | 6,365 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 4,444 | 24,313 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 2,694 | 5,388 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 2,260 | 22,053 (0%) | 0% | 26.7 | 60,432 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,861 | 23,914 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,861 | 1,861 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,750 | 5,250 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 956 | 22,958 (0%) | 0% | 26.7 | 25,563 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jul 2024 | 24,248 | 40,412 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 24.79 per share. | 23 Jul 2024 | 24,248 | 19,253 (0%) | 0% | 24.8 | 601,108 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 23 Jul 2024 | 24,248 | 43,501 (0%) | 0% | 11.1 | 269,153 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2024 | 991 | 990 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2024 | 991 | 19,762 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.88 per share. | 26 Apr 2024 | 509 | 19,253 (0%) | 0% | 17.9 | 9,101 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 33,150 | 33,150 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 6,365 | 11,615 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 5,092 | 5,092 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,694 | 19,562 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,694 | 8,921 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Mark Ragosa | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 04 Apr 2024 | 791 | 18,771 (0%) | 0% | 17.9 | 14,159 | Class A Common Share |